Repligen Reports Third Quarter 2020 Financial Results and Updates Full Year 2020 Financial Guidance

Rhea-AI Summary

Repligen Corporation (NASDAQ:RGEN) reported record quarterly revenue of $94.1 million, marking a 35% year-over-year growth with 31% organic growth. The company raised its full-year revenue guidance to $348-$352 million, implying a 29%-30% total revenue growth. COVID-related revenues contributed approximately 14% to quarterly revenue and 55% to growth. Repligen also completed the acquisition of Non-Metallic Solutions and plans to acquire ARTeSYN Biosolutions, enhancing its systems strategy.

Positive

• Quarterly revenue increased to $94.1 million, up 35% year-over-year.
• Organic revenue growth of 31%.
• Raised full-year revenue guidance to $348-$352 million.
• Operating margin increased to 22.3%, reflecting strong efficiency.
• EPS improved to $0.27 GAAP and $0.40 adjusted.

Negative

• None.

• Reports record quarterly revenue of $94.1 million with strong margin expansion
  
• Overall revenue grew 35% year-over-year, with organic growth of 31%
• Raises revenue guidance to $348-$352 million and overall revenue growth to 29%-30% for full year 2020, representing 23%-24% organic growth
• Completes acquisition of Non-Metallic Solutions and announces agreement to acquire bioprocess systems innovator ARTeSYN Biosolutions

WALTHAM, Mass., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its third quarter of 2020. Provided in this press release are financial highlights for the three- and nine- month periods ended September 30, 2020, updates to our financial guidance for the fiscal year 2020 and access information for today’s webcast and conference call.

Tony J. Hunt, President and Chief Executive Officer said, “We are pleased with our momentum during the third quarter, reporting over $94 million in revenue and robust organic growth of 31%. COVID programs accounted for approximately 14% of revenue during the quarter, and approximately 55% of revenue growth. We continued to see strong revenue and order demand as both COVID customers and gene therapy accounts drove accelerated growth across our franchises, with Filtration performing exceptionally well. Direct product orders were up over 100% year-on-year, positioning us well for an excellent finish to 2020 and a strong start to 2021.”

Mr. Hunt added, “In addition to our strong business performance we were delighted to close on our deal to acquire Non-Metallic Solutions and also sign an agreement to acquire ARTeSYN Biosolutions. These acquisitions broaden and strengthen our systems strategy - where single-use systems and consumables - including flow path assemblies - come together for an enhanced customer offering with meaningful process and yield advantages.”

Financial Highlights for the Third Quarter 2020

• Revenue increased by 35% year-over-year as reported and 31% organically, to reach a quarterly record $94.1 million.
• Gross margin (GAAP) was 57.9%, an increase of 3.1 points, and adjusted gross margin (non-GAAP) was 58.0%, an increase of 1.9 points compared to third quarter of 2019.
• Operating margin (GAAP) was 22.3%, an increase of 10.8 points, and adjusted operating margin (non-GAAP) was 28.6%, an increase of 6.8 points compared to the third quarter of 2019.
• Fully diluted EPS (GAAP) increased to $0.27 compared to $0.03 for the third quarter of 2019, and adjusted fully diluted EPS (non-GAAP) increased to $0.40 compared to $0.26 for the third quarter of 2019.

Financial Details for the Third Quarter and First Nine Months of 2020

REVENUE

• Total revenue for the third quarter of 2020 increased to $94.1 million compared to $69.4 million for the third quarter of 2019, a year-over-year gain of 35% as reported and 34% at constant currency, with organic growth of 31%.
• Total revenue for the first nine months of 2020 increased to $257.6 million compared to $200.8 million for the first nine months of 2019, a year-over-year gain of 28% as reported and at constant currency, with organic growth of 22%.

GROSS PROFIT and GROSS MARGIN

• Gross profit (GAAP) for the third quarter of 2020 was $54.4 million, a year-over-year increase of $16.4 million and representing 57.9% gross margin.
• Adjusted gross profit (non-GAAP) for the third quarter of 2020 was $54.6 million, a year-over-year increase of $15.6 million and representing 58% gross margin.
• Gross profit (GAAP) for the first nine months of 2020 was $149.1 million, a year-over-year increase of $37.3 million and representing 57.9% gross margin.
• Adjusted gross profit (non-GAAP) for the first nine months of 2020 was $150.0 million, a year-over-year increase of $35.7 million and representing 58.2% gross margin.

OPERATING INCOME

• Operating income (GAAP) for the third quarter of 2020 was $21.0 million, an increase of $13 million compared to $8.0 million for the third quarter of 2019. Adjusted operating income (non-GAAP) for the third quarter of 2020 was $26.9 million, an increase of $11.7 million compared to $15.1 million for the third quarter of 2019.
• Operating income (GAAP) for the first nine months of 2020 was $52.4 million, an increase of $22.2 million compared to $30.2 million for the first nine months of 2019. Adjusted operating income (non-GAAP) for the first nine months of 2020 was $70.8 million, an increase of $20.0 million compared to $50.8 million for the first nine months of 2019.

NET INCOME

• Net income (GAAP) for the third quarter of 2020 was $14.6 million, an increase of $12.9 million compared to $1.7 million for the third quarter of 2019. Adjusted net income (non-GAAP) for the third quarter of 2020 was $21.2 million, an increase of $7.8 million compared to $13.3 million for the third quarter of 2019.
• Net income (GAAP) for the first nine months of 2020 was $40.2 million, an increase of $22.4 million compared to $17.8 million for the first nine months of 2019. Adjusted net income (non-GAAP) for the first nine months of 2020 was $60.4 million, an increase of $18.7 million compared to $41.7 million for the first nine months of 2019.

EARNINGS PER SHARE

• Earnings per share (GAAP) for the third quarter of 2020 increased to $0.27 on a fully diluted basis, compared to $0.03 for the third quarter of 2019. Adjusted EPS (non-GAAP) for the third quarter of 2020 increased to $0.40 on a fully diluted basis, compared to $0.26 for the 2019 period.
• Earnings per share (GAAP) for the first nine months of 2020 increased to $0.75 on a fully diluted basis, compared to $0.37 for the first nine months of 2019. Adjusted EPS (non-GAAP) for the first nine months of 2020 increased to $1.13 on a fully diluted basis, compared to $0.87 for the first nine months of 2019.

EBITDA

• EBITDA, a non-GAAP financial measure, increased to $27.4 million for the third quarter of 2020, compared to $8.4 million for the third quarter of 2019. Adjusted EBITDA for the third quarter of 2020 increased to $29.4 million, compared to $17.3 million for the third quarter of 2019.
• EBITDA increased to $71.4 million for the first nine months of 2020, compared to $39.3 million for the first nine months of 2019. Adjusted EBITDA for the first nine months of 2020 increased to $78.0 million, compared to $56.5 million for the first nine months of 2019.

CASH

• Our cash and cash equivalents at September 30, 2020 were $553.3 million, an increase of $24.9 million from $528.4 million at December 31, 2019.
  

All reconciliations of GAAP to adjusted (non-GAAP) figures above, as well as EBITDA to adjusted EBITDA, are detailed in the reconciliation tables included later in this press release.

Financial Guidance for 2020

Our financial guidance for the fiscal year 2020 is based on expectations for our existing business and includes the financial impact of our acquisitions of C Technologies (which closed on May 31, 2019), Engineered Molding Technology (which closed on July 13, 2020) and Non-Metallic Solutions, Inc. (which closed on October 20, 2020). The guidance below does not include the impact of our proposed acquisition of ARTeSYN Biosolutions, which is expected to close during the fourth quarter of 2020. The guidance also excludes the impact of potential additional acquisitions and future fluctuations in foreign currency exchange rates. 

FISCAL YEAR 2020 GUIDANCE:

• Total revenue is projected to be in the range of $348-$352 million, an increase from our previous guidance of $332-$340 million. This updated revenue guidance includes approximately $1 million in projected revenue from Non-Metallic Solutions, and reflects overall revenue growth of 29%-30%, with organic revenue growth in the range of 23%-24%.
  
  
• COVID programs are expected to account for approximately 10% of revenue.
  
  
• Gross margin is expected to be in the range of 57.5%-58.0% on both a GAAP and non-GAAP basis, compared to our previous guidance of 56.5%-57%.

• Income from operations is expected to be in the range of $66-$68 million on a GAAP basis, an increase from our previous guidance of $59-$62 million. Adjusted income from operations (non-GAAP) is expected to be in the range of $91-$93 million, an increase from our previous guidance of $81-$84 million.
  
  
• Net income is expected to be in the range of $47.5-$49.5 million on a GAAP basis, an increase from our previous guidance of $41-$44 million. Adjusted net income (non-GAAP) is expected to be in the range of $75-$77 million, an increase from our previous guidance of $66-$69 million. Our current guidance reflects an adjusted tax rate of 17% on adjusted pre-tax income, compared to our previous guidance of 18%.
  
  
• Fully diluted EPS (GAAP) is expected to be in the range of $0.89-$0.93, an increase from our previous guidance of $0.77-$0.82. Adjusted fully diluted EPS (non-GAAP) is expected to be in the range of $1.41-$1.45, an increase from our previous guidance of $1.24-$1.29.
  

Our non-GAAP guidance for the fiscal year 2020 excludes the following items:

• $9.2 million estimated acquisition and integration expenses; $0.5 million in cost of product revenue, $0.5 million in R&D and $8.2 million in selling, general and administrative expense (“SG&A”).
  
  
• Expected inventory step-up charges of $0.2 million related to the acquisitions of Engineered Molding Technology and Non-Metallic Solutions.
  
  
• $15.8 million estimated intangible amortization expense; $0.3 million in cost of product revenue and $15.6 million in SG&A.
  
  
• $11.0 million of non-cash interest expense (Other income (expense)) related to our convertible debt notes.
  

Our non-GAAP guidance for the fiscal year 2020 includes:

• An income tax expense of $8.6 million, representing the tax impact of acquisition and integration, inventory step-up, and intangible amortization expenses, as well as non-cash interest expenses related to our convertible debt notes.
  

All reconciliations of GAAP to adjusted (non-GAAP) guidance are detailed in the tables included later in this press release.

Conference Call
Repligen will host a conference call and webcast today, November 5, 2020, at 8:30 a.m. EST, to discuss third quarter 2020 financial results and corporate developments. The conference call will be accessible by dialing toll-free (844) 763-8274 for domestic callers or (412) 717-9224 for international callers. No passcode is required for the live call. In addition, a webcast will be accessible via the Investor Relations section of the Company’s website. Both the conference call and webcast will be archived for a period of time following the live event. The replay dial-in numbers are (877) 344-7529 from the U.S., (855) 669-9658 from Canada and (412) 317-0088 for international callers. Replay listeners must provide the passcode 10149396.

Non-GAAP Measures of Financial Performance
To supplement our financial statements, which are presented on the basis of U.S. generally accepted accounting principles (GAAP), the following non-GAAP measures of financial performance are included in this release: revenue growth rate at constant currency, adjusted gross profit and adjusted gross margin, adjusted income from operations and adjusted operating margin, earnings before interest, taxes, depreciation and amortization (EBITDA), adjusted EBITDA, adjusted net income, adjusted net income per share, adjusted earnings per diluted share (EPS), adjusted cost of sales, adjusted research & development expense, adjusted SG&A, adjusted income tax expense and adjusted income tax rate. The Company provides organic revenue growth rates in constant currency to exclude the impact of both foreign currency translation, and the impact of acquisition revenue for current year periods that have no prior year comparable, in order to facilitate a comparison of its current revenue performance to its past revenue performance. The Company provides revenue growth rates in constant currency in order to facilitate a comparison of its current revenue performance to its past revenue performance. To calculate revenue growth rates in constant currency, the Company converts actual net sales from local currency to U.S. dollars using constant foreign currency exchange rates in the current and prior period.

The Company’s non-GAAP financial results and/or non-GAAP guidance exclude the impact of: acquisition and integration costs, inventory step-up charges and intangible amortization costs related to the Company’s acquisitions, as well as non-cash interest expenses related to the Company’s convertible debt, and the related impact on tax of non-GAAP charges. These costs are excluded because management believes that such expenses do not have a direct correlation to future business operations, nor do the resulting charges recorded accurately reflect the performance of our ongoing operations for the period in which such charges are recorded.

A reconciliation of GAAP to adjusted (non-GAAP) financial measures, as well as EBITDA to adjusted EBITDA, is included as an attachment to this press release. When analyzing the Company’s operating performance and guidance, investors should not consider non-GAAP measures as substitutable for the comparable financial measures prepared in accordance with GAAP.

About Repligen Corporation
Repligen Corporation is a global life sciences company that develops and commercializes highly innovative bioprocessing technologies and systems that increase efficiencies in the process of manufacturing biological drugs. We are inspiring advances in bioprocessing for the customers we serve; primarily biopharmaceutical drug developers and contract development and manufacturing organizations (CDMOs) worldwide. Our corporate headquarters are located in Waltham, MA (USA), and we have additional administrative and manufacturing operations in Rancho Dominguez, CA; Marlborough and Auburn, MA; Bridgewater, NJ; Clifton Park, NY; Dallas, TX; Ravensburg, Germany; Breda, the Netherlands and Lund, Sweden.

The following constitutes a “Safe Harbor” statement under the Private Securities Litigation Reform Act of 1995: This press release contains forward-looking statements, which are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Investors are cautioned that statements in this press release which are not strictly historical statements, including, without limitation, express or implied statements or guidance regarding current or future financial performance and position, including cash and investment position, demand in the markets in which we operate, the expected performance of our business, the expected performance of the C Technologies, Engineered Molding Technology and Non-Metallic Solutions businesses, the expected closing of the acquisition of ARTeSYN Biosolutions, the expected performance and success of our strategic partnerships, management’s strategy, plans and objectives for future operations or acquisitions, product development and sales, selling, general and administrative expenditures, intellectual property, development and manufacturing plans, availability of materials and product and adequacy of capital resources, our financing plans, and the projected impact of, and response to, the COVID-19 coronavirus pandemic on our business and on the U.S. and global economies constitute forward-looking statements identified by words like “believe,” “expect,” “may,” “will,” “should,” “seek,” “anticipate,” or “could” and similar expressions. Such forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated, including, without limitation, risks associated with the following: the effect of the COVID-19 coronavirus pandemic, including mitigation efforts and economic effects, on our business operations and the operations of our customers and suppliers; the ultimate impact of the COVID-19 coronavirus pandemic on our business or financial results; our ability to successfully grow our bioprocessing business, including as a result of acquisition, commercialization or partnership opportunities; our ability to successfully integrate any acquisitions, our ability to develop and commercialize products and the market acceptance of our products; our ability to integrate the C Technologies, Engineered Molding Technology and Non-Metallic Solutions businesses successfully into our business and achieve the expected benefits of the acquisitions; reduced demand for our products that adversely impacts our future revenues, cash flows, results of operations and financial condition; our ability to compete with larger, better financed bioprocessing, pharmaceutical and biotechnology companies; our compliance with all U.S. Food and Drug Administration and EMEA regulations; our volatile stock price; and other risks detailed in Repligen’s Annual Report on Form 10-K for the year ended December 31, 2019 and Quarterly Report on Form 10-Q for the quarter ended March 31, 2020 on file with the Securities and Exchange Commission and the other reports that Repligen periodically files with the Securities and Exchange Commission. Actual results may differ materially from those Repligen contemplated by these forward-looking statements. These forward-looking statements reflect management’s current views and Repligen does not undertake to update any of these forward-looking statements to reflect a change in its views or events or circumstances that occur after the date hereof except as required by law.

Repligen Contact:
Sondra S. Newman
Global Head of Investor Relations
(781) 419-1881
investors@repligen.com

REPLIGEN CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited, amounts in thousands, except share and per share data)
	Three Months Ended September 30,								Nine Months Ended September 30,
		2020				2019				2020				2019
Revenue:
Product revenue	$	94,029			$	69,419			$	257,521			$	200,701
Royalty and other revenue		31				26				91				70
Total revenue		94,060				69,445				257,612				200,771
Costs and expenses:
Cost of product revenue		39,626				31,425				108,471				88,978
Research and development		4,422				5,427				13,460				14,278
Selling, general and administrative		29,051				24,629				83,277				67,326
		73,099				61,481				205,208				170,582
Income from operations		20,961				7,964				52,404				30,189
Investment income		82				1,898				1,699				3,616
Loss on extinguishment of debt		-				(5,650	)			-				(5,650	)
Interest expense		(3,052	)			(2,857	)			(9,032	)			(6,326	)
Other (expense) income, net		(248	)			316				(632	)			(23	)
Income before income taxes		17,743				1,671				44,439				21,806
Income tax provision		3,191				12				4,211				3,999
Net income	$	14,552			$	1,659			$	40,228			$	17,807
Earnings per share:
Basic	$	0.28			$	0.03			$	0.77			$	0.38
Diluted	$	0.27			$	0.03			$	0.75			$	0.37
Weighted average shares outstanding:
Basic		52,545,100				50,851,623				52,341,037				47,086,779
Diluted		53,468,658				51,809,289				53,299,544				47,929,581
Balance Sheet Data:	September 30, 2020				December 31, 2019
Cash, cash equivalents and marketable securities	$	553,302			$	528,392
Working capital		645,744				593,515
Total assets		1,476,316				1,400,113
Long-term obligations		300,462				292,032
Accumulated earnings		46,071				5,843
Stockholders' equity		1,124,870				1,059,768

REPLIGEN CORPORATION
RECONCILIATION OF GAAP INCOME FROM OPERATIONS TO NON-GAAP (ADJUSTED) INCOME FROM OPERATIONS
(Unaudited, amounts in thousands)
			Three Months Ended September 30,								Nine Months Ended September 30,
				2020				2019				2020				2019
GAAP INCOME FROM OPERATIONS			$	20,961			$	7,964			$	52,404			$	30,189
ADJUSTMENTS TO INCOME (LOSS) FROM OPERATIONS:
		Acquisition and integration costs		1,849				2,953				6,536				9,573
		Intangible amortization		3,925				3,900				11,677				9,562
		Inventory step-up charges		144				314				144				1,483
ADJUSTED INCOME FROM OPERATIONS			$	26,879			$	15,131			$	70,761			$	50,807
REPLIGEN CORPORATION
RECONCILIATION OF GAAP NET INCOME TO NON-GAAP (ADJUSTED) NET INCOME
(Unaudited, amounts in thousands)
			Three Months Ended September 30,								Nine Months Ended September 30,
				2020				2019				2020				2019
GAAP NET INCOME			$	14,552			$	1,659			$	40,228			$	17,807
ADJUSTMENTS TO NET INCOME:
		Acquisition and integration costs		1,849				2,953				6,536				10,074
		Inventory step-up charges		144				314				144				1,483
		Intangible amortization		3,925				3,900				11,677				9,562
		Loss on extinguishment of debt		-				5,650				-				5,650
		Non-cash interest expense		2,759				2,631				8,174				4,863
		Tax effect of non-GAAP charges		(2,072	)			(3,781	)			(6,334	)			(7,742	)
ADJUSTED NET INCOME			$	21,157			$	13,326			$	60,425			$	41,697
REPLIGEN CORPORATION
RECONCILIATION OF GAAP NET INCOME PER SHARE TO NON-GAAP (ADJUSTED) NET INCOME PER SHARE
(Unaudited)
			Three Months Ended September 30,								Nine Months Ended September 30,
				2020				2019				2020				2019
GAAP NET INCOME PER SHARE - DILUTED			$	0.27			$	0.03			$	0.75			$	0.37
ADJUSTMENTS TO NET INCOME PER SHARE - DILUTED:
		Acquisition and integration costs		0.03				0.06				0.12				0.21
		Inventory step-up charges		0.00				0.01				0.00				0.03
		Intangible amortization		0.07				0.08				0.22				0.20
		Loss on extinguishment of debt		-				0.11				-				0.12
		Non-cash interest expense		0.05				0.05				0.15				0.10
		Tax effect of non-GAAP charges		(0.04	)			(0.07	)			(0.12	)			(0.16	)
ADJUSTED NET INCOME PER SHARE - DILUTED				0.40			$	0.26			$	1.13			$	0.87
Totals may not add due to rounding.
REPLIGEN CORPORATION
RECONCILIATION OF GAAP NET INCOME TO ADJUSTED EBITDA
(Unaudited, amounts in thousands)
			Three Months Ended September 30,								Nine Months Ended September 30,
				2020				2019				2020				2019
GAAP NET INCOME			$	14,552			$	1,659			$	40,228			$	17,807
ADJUSTMENTS:
		Investment Income		(82	)			(1,898	)			(1,699	)			(3,616	)
		Interest Expense		3,052				2,857				9,032				6,326
		Tax Provision		3,191				12				4,211				3,999
		Depreciation		2,757				1,810				7,820				5,147
		Amortization(1)		3,953				3,928				11,760				9,644
EBITDA				27,422				8,368				71,353				39,307
OTHER ADJUSTMENTS:
		Acquisition and integration costs		1,849				2,953				6,536				10,074
		Loss on extinguishment of debt		-				5,650				-				5,650
		Inventory step-up charges		144				314				144				1,483
ADJUSTED EBITDA			$	29,415			$	17,285			$	78,033			$	56,514
(1	)	Includes amortization of milestone payments in accordance with GAAP of $28 and $83 for the three- and nine-months ended September 30, 2020 and 2019.
REPLIGEN CORPORATION
RECONCILIATION OF GAAP COST OF SALES TO NON-GAAP (ADJUSTED) COST OF SALES
(Unaudited, amounts in thousands)
			Three Months Ended September 30,								Nine Months Ended September 30,
				2020				2019				2020				2019
GAAP COST OF SALES			$	39,626			$	31,425			$	108,471			$	88,978
ADJUSTMENT TO COST OF SALES:
		Acquisition and integration costs		(3	)			(519	)			(468	)			(670	)
		Inventory step-up charges		(144	)			(314	)			(144	)			(1,483	)
		Intangible amortization		-				(128	)			(254	)			(392	)
ADJUSTED COST OF SALES			$	39,479			$	30,464			$	107,605			$	86,433
REPLIGEN CORPORATION
RECONCILIATION OF GAAP R&D EXPENSE TO NON-GAAP (ADJUSTED) R&D EXPENSE
(Unaudited, amounts in thousands)
			Three Months Ended September 30,								Nine Months Ended September 30,
				2020				2019				2020				2019
GAAP R&D			$	4,422			$	5,427			$	13,460			$	14,278
ADJUSTMENT TO R&D:
		Acquisition and integration costs		(1	)			(278	)			(472	)			(405	)
ADJUSTED R&D			$	4,421			$	5,149			$	12,988			$	13,873
REPLIGEN CORPORATION
RECONCILIATION OF GAAP SG&A EXPENSE TO NON-GAAP (ADJUSTED) SG&A EXPENSE
(Unaudited, amounts in thousands)
			Three Months Ended September 30,								Nine Months Ended September 30,
				2020				2019				2020				2019
GAAP SG&A EXPENSE			$	29,051			$	24,629			$	83,277			$	67,326
ADJUSTMENTS TO SG&A EXPENSE:
		Acquisition and integration costs		(1,845	)			(2,156	)			(5,596	)			(8,499	)
		Intangible amortization		(3,925	)			(3,772	)			(11,425	)			(9,170	)
ADJUSTED SG&A EXPENSE			$	23,280			$	18,701			$	66,257			$	49,657

REPLIGEN CORPORATION
RECONCILIATION OF GAAP NET INCOME GUIDANCE TO ADJUSTED (NON-GAAP NET INCOME GUIDANCE)
(in thousands)		Twelve months ending December 31, 2020
		Low End				High End
GUIDANCE ON NET INCOME		$	47,500			$	49,500
ADJUSTMENTS TO GUIDANCE ON NET INCOME:
	Acquisition and integration costs		9,167				9,167
	Anticipated pre-tax amortization of
	acquisition-related intangible assets		15,842				15,842
	Inventory step-up costs		172				172
	Non-cash interest expense		10,966				10,966
	Tax effect of non-GAAP charges		(8,630	)			(8,630	)
	Guidance rounding adjustment		(17	)			(17	)
GUIDANCE ON ADJUSTED NET INCOME		$	75,000			$	77,000
REPLIGEN CORPORATION
RECONCILIATION OF GAAP NET INCOME PER SHARE GUIDANCE TO
ADJUSTED (NON-GAAP) NET INCOME PER SHARE GUIDANCE
		Twelve months ending December 31, 2020
		Low End				High End
GUIDANCE ON NET INCOME PER SHARE - DILUTED		$	0.89			$	0.93
ADJUSTMENTS TO GUIDANCE ON NET INCOME PER SHARE - DILUTED:
	Acquisition and integration costs	$	0.17			$	0.17
	Anticipated pre-tax amortization of
	acquisition-related intangible assets	$	0.30			$	0.30
	Inventory step-up costs	$	0.00			$	0.00
	Non-cash interest expense	$	0.21			$	0.21
	Tax effect of non-GAAP charges	($	0.16	)		($	0.16	)
	Guidance rounding adjustment	($	0.00	)		$	0.00
GUIDANCE ON ADJUSTED NET INCOME PER SHARE - DILUTED		$	1.41			$	1.45
Totals may not add due to rounding.

FAQ

What were Repligen's third-quarter earnings results for 2020?

Repligen reported third-quarter 2020 earnings of $94.1 million, a 35% increase from $69.4 million in the same quarter of 2019.

What is Repligen's revenue guidance for 2020?

Repligen raised its revenue guidance for 2020 to a range of $348-$352 million.

How did COVID programs impact Repligen's revenue?

COVID programs accounted for approximately 14% of Repligen's revenue in the third quarter, contributing to about 55% of revenue growth.

What acquisitions did Repligen announce?

Repligen completed the acquisition of Non-Metallic Solutions and announced an agreement to acquire ARTeSYN Biosolutions.

What is the expected EPS for Repligen in 2020?

Repligen expects fully diluted EPS to be in the range of $0.89-$0.93 for the fiscal year 2020.